The mouse blood-brain barrier admits 92 of 861 plasma proteins and directs them to different cells; delivery of the cholesterol carrier APOA1 declines in an early Alzheimer's disease model while the barrier remains intact
The mouse blood-brain barrier admits 92 of 861 plasma proteins and directs them to different cells; delivery of the cholesterol carrier APOA1 declines in an early Alzheimer's disease model while the barrier remains intact
On November 11, Cell published a study by Andrew Yang's group at the Gladstone Institutes on how blood proteins enter the mouse brain through the blood-brain barrier, a layer of cells in the walls of brain blood vessels. APOA1 reached astrocytes, cells that support neurons; increasing its production in the liver improved some outcomes in mice modeling Alzheimer's disease.
“The prevailing view in the field was that the blood-brain barrier is normally impermeable and becomes leaky in Alzheimer's disease,” Yang told Nature. In 2020, he labeled hundreds of mouse plasma proteins and showed in a Nature paper that they enter the healthy brain. Which proteins crossed, which cells received them, and what they did in the brain remained unknown.
The researchers chemically labeled mouse plasma proteins, injected them into other mice, and examined the brain's blood vessels and tissue separately for labeled proteins. Of 861 proteins, 92 entered brain tissue, 99 remained in blood vessel walls, and the remaining 670 were detected in neither the vessels nor the brain tissue. The 92 proteins are produced mainly by the liver, adipose tissue, and intestine.
APOA1 goes to astrocytes, while SERPINA1 goes to microglia, the brain's immune cells. The brain produces almost no APOA1; it receives the protein from the blood. A 2021 study showed that mice lacking the APOA1 gene in the liver and intestine also lacked the protein in their cerebrospinal fluid. The receptor SR-B1 allows APOA1 to cross the blood vessel wall: increasing SR-B1 production in blood vessels increased APOA1 delivery. Cultured astrocytes took up APOA1 through the receptor ABCA1, whose gene is among those associated with Alzheimer's disease risk. Receptors on recipient cells determine where APOA1 goes: increasing SR-B1 production in neurons redirected the protein from astrocytes to neurons.
Astrocytes that take up APOA1 lose stored lipids and release cholesterol. Culture medium from these astrocytes increased cholesterol levels in cultured neurons and the number of spines on which synapses form. APOA1 did not produce these changes in neurons in the absence of astrocytes.
5xFAD mice carry human mutations that cause amyloid protein plaques to accumulate in the brain. In 18-week-old mice, the barrier remained intact according to the authors, but delivery of three proteins, including APOA1, decreased, while delivery of four, including SERPINA1, increased. In 4,5-month-old mice, SR-B1 levels in blood vessels and ABCA1 levels in astrocytes declined, and astrocytes accumulated lipids. Injection of the bacterial toxin LPS, by contrast, disrupted the barrier, allowing 225 plasma proteins to enter the brain indiscriminately. “Before the barrier starts letting harmful proteins into the brain, it stops letting beneficial ones through,” first author Haoyue Zhou says in the Gladstone press release.
Because APOA1 comes from the blood, the researchers increased its production in the liver: they injected eight-week-old 5xFAD mice with a liver-targeted viral vector carrying the APOA1 gene and followed them for 2,5 months. Lipid accumulation in astrocytes approached the level seen in healthy mice. Synapse numbers increased in the hippocampus, a memory center, while plaque numbers decreased only in its dentate gyrus. Two of the four behavioral measures returned to normal: hyperactivity and preference for a novel maze arm, a measure of memory.
The authors suggest that the pathways they identified across the barrier could expand the range of drug-delivery “shuttles.” According to a 2005 estimate they cite, the barrier prevents more than 98% of small-molecule drugs and most biologics from entering the brain.